MASON, Ohio--(BUSINESS WIRE)--Oct. 24, 2016--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage (LAA) management,
today announced that it will present at the Stifel Healthcare Conference
at the Lotte New York Palace Hotel in New York City on Tuesday, November
15, 2016. Management is scheduled to present at 9:30 a.m. Eastern Time.
A live audio webcast of the presentation may be accessed by visiting the
Investors page of AtriCure’s corporate website at www.atricure.com.
A replay of the presentation will be available for 90 days following the
presentation.
AtriCure management will also be presenting at the Canaccord Medical
Technologies & Diagnostics Forum at the Westin Grand Central in New York
City on Thursday, November 17, 2016. Management is scheduled to present
at 2:00 p.m. Eastern Time. A live audio webcast of the presentation may
be accessed by visiting the Investors page of AtriCure’s corporate
website at www.atricure.com.
A replay of the presentation will be available for 90 days following the
presentation.
About AtriCure, Inc.
AtriCure, Inc. provides innovative technologies for the treatment of
Afib and related conditions. Afib affects more than 33 million people
worldwide. Electrophysiologists and cardiothoracic surgeons around the
globe use AtriCure technologies for the treatment of Afib and reduction
of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation
System is the first and only medical device to receive FDA approval for
the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial
Appendage Exclusion System products are the most widely sold LAA
management devices worldwide, with more than 75,000 implanted to date.
For more information, visit AtriCure.com
or follow us on Twitter @AtriCure.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024006500/en/
Source: AtriCure, Inc.
AtriCure, Inc.
Andy Wade
Senior Vice President and
Chief Financial Officer
513-755-4564
awade@atricure.com
or
Investor
Relations
Lynn Pieper Lewis
Gilmartin Group
415-937-5402
lynn@gilmartinir.com
